


Amendments to the Claims

1. (Original) A compound of formula I




wherein R_1 , R_2 , R_3 , R_4 are all or partly hydrogen atoms, or alkyl containing 1 to 5 carbon atoms; and pharmaceutically acceptable salts thereof.

2. (Original) Compound of formula I according to claim 1, wherein R_1 , R_2 , R_3 , R_4 are all hydrogen atoms.

3. (Original) Compound of formula I according to claim 2, characterized in that the compound is derived from cottonseeds.

4. (Original) Compound of formula I according to claim 1, which is quercetin-3-O- β -D-apiofuranosyl-(1 \rightarrow 2)-[α -D-rhamnopyranosyl-(1 \rightarrow 6)]- β -D-glucopyranoside.

5. (Original) A pharmaceutical composition comprising compound of formula I,



wherein R₁, R₂, R₃, R₄ are all or partly hydrogen atoms, or alkyl containing 1 to 5 carbon atoms; and pharmaceutical carriers.

6. (Original) Pharmaceutical composition according to claim 5, for the treatment of diseases or symptoms related to 5HT_{1A} receptor, including depression, anxiety, Alzheimer's disease, drug or alcohol dependence, sleep disorders or panic state.


7. (Original) Pharmaceutical composition according to claim 5, for protection of neuron cells, including delaying senility, improving learning and memory, preventing and treating neuron cell damages caused by various kinds of cerebral damages.

8. (Currently Amended) Pharmaceutical composition according to ~~any one of claims 5 to 7~~ claim 5, wherein the pharmaceutical carriers are adjuvants for use in solid medicaments including disintegrants, diluting agents, binders, lubricants, etc, and those

for use in liquid medicaments including solvents, pH adjusting agents, osmotic regulators, antioxidants, metal complexing agents, preservatives, flavoring agents, etc.

9. (Original) Pharmaceutical composition according to claim 5, wherein R_1 , R_2 , R_3 , R_4 of formula I are all hydrogen atoms.

10. (Original) Use of compound of formula I,



for the preparation of medicaments for the treatment of diseases related to 5HT_{1A} receptor or for protection of neuron cells.

11. (Original) Use according to claim 10, wherein R_1 , R_2 , R_3 , R_4 of formula I are all hydrogen atoms.

12. (New) Pharmaceutical composition according to claim 6, wherein the pharmaceutical carriers are adjuvants for use in solid medicaments including disintegrants, diluting agents, binders, lubricants, etc, and those for use in liquid

medicaments including solvents, pH adjusting agents, osmotic regulators, antioxidants, metal complexing agents, preservatives, flavoring agents, etc.

13. (New) Pharmaceutical composition according to claim 7, wherein the pharmaceutical carriers are adjuvants for use in solid medicaments including disintegrants, diluting agents, binders, lubricants, etc, and those for use in liquid medicaments including solvents, pH adjusting agents, osmotic regulators, antioxidants, metal complexing agents, preservatives, flavoring agents, etc.